|
|
|
| Association of genetic polymorphisms in SLC22A1 and SLC22A2 with intolerance to metformin in type 2 diabetes |
| FU Ting1,2,SHI Jiandang3,KUANG Xia2,and WANG Suli1,2 |
1.Department of Internal Medicine,Hebei Medical University,Shijiazhuang 050000,China;
2.Department of Endocrinology,The Affiliated Hospital of Logistics University of Chinese People’s Armed Police Force,Tianjin 300162,China;
3.College of Life Sciences,Nankai University, Tianjin 300017, China |
|
|
|
|
Abstract Objective To study the relationship between gene polymorphisms of 1222A＞G in SLC22A1 and 808G＞T in SLC22A2 with the gastrointestinal side-effects in metformin-treated type 2 diabetes patients.Methods One hundred and thirty type 2 diabetes patients treated with metformin at the first time were recruited.Genomic DNA samples were extracted from the patients’ leukocytes in the peripheral blood.The genotypes were determined by the allele-specific polymerase chain reaction(AS-PCR)and gel electrophoresismethod.Results Three genotypes of AA, AG, GG were found in SLC22A11222A＞G site and the mutation frequency was 64.62%.An allele of 1222A＞G was associated with the incidence of gastrointestinal side-effects of metformin(P＜0.05).Three genotypes of GG, GT, TT were found in SLC22A2 808G＞T site and the mutation frequency was 11.15%.The incidence of gastrointestinal side effects in metformin-treated type 2 diabetes patients with different genotypes had no significant differences(P＝0.559).The patients in metformin intolerance group were older than the patients in metformin tolerance group. The patients in metformin intolerance group had higher systolic blood pressure than the patients in metformin tolerance group.Conclusions SLC22A11222A＞G gene polymorphis was associated with the incidence of gastrointestinal side effects in metformin-treated type 2 diabetes patients, however SLC22A2 808G＞T is not.Older age and high systolic blood pressure may be the risk factors for metformin intolerance.
|
|
Received: 11 November 2015
|
|
|
|
|
|
| [1] |
Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists′ comprehensive diabetes management algorithm 2013 consensus statement-executive summary[J]. Endocr Pract, 2013,19(3):536-557.
|
| [2] |
Ma J, Liu LY, Wu PH, et al. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China[J]. J Diabetes Res, 2014,2014:294017.
|
| [3] |
Wang H, Ni Y, Yang S, et al. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus[J]. Curr Ther Res Clin Exp, 2013,75:88-92.
|
| [4] |
Sin HY, Kim JY, Jung KH. Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin[J]. Arch Pharm Res, 2011,34(1):99-107.
|
| [5] |
Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment[J]. Int J Mol Sci, 2013,14(11):22933-22966.
|
| [6] |
Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility[J]. Cochrane Database Syst Rev, 2010,(1):CD003053.
|
| [7] |
Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders[J]. Diabetes Metab, 2011,37(2):90-96.
|
| [8] |
Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1[J]. Drug Metab Pharmacokinet, 2005,20(5):379-386.
|
| [9] |
Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin[J]. Pharmacogenet Genomics, 2009,19(7):497-504.
|
| [10] |
Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function[J]. Pharmacogenetics, 2002,12(5):395-405.
|
| [11] |
Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients[J]. Pharmacogenet Genomics, 2012,22(9):659-666.
|
| [12] |
Dujic T, Zhou K, Donnelly LA, et al. Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study[J]. Diabetes, 2015,64(5):1786-1793.
|
| [13] |
Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update[J]. Ann Intern Med, 2002,137(1):25-33.
|
| [14] |
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science, 1999,286(5439):487-491.
|
| [15] |
Ieiri I, Takane H, Hirota T, et al. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy[J]. Expert Opin Drug Metab Toxicol, 2006,2(5):651-674.
|
| [16] |
Li Q, Liu F, Zheng TS, et al. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin[J]. Acta Pharmacol Sin, 2010,31(2):184-190.
|
| [17] |
Wang ZJ, Yin OQ, Tomlinson B, et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine[J]. Pharmacogenet Genomics, 2008,18(7):637-645.
|
| [18] |
Kang HJ, Song IS, Shin HJ, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population[J]. Drug Metab Dispos, 2007,35(4):667-675.
|
| [19] |
Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin[J]. Clin Pharmacol Ther, 2009,86(3):299-306.
|
| [20] |
Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin[J]. Clin Pharmacol Ther, 2008,84(5):559-562.
|
| [21] |
Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine[J]. Drug Metab Dispos, 2007,35(10):1956-1962.
|
|
|
|
2016, Vol. 27 
